Posted on 27 November 2014
Tags: diagnostic, financings
Quotient has entered into agreements to issue to certain subscribers 2,000,000 ordinary shares at $9.50 per share and 850,000 pre-funded warrants at $9.49 per warrant, exercisable for up to 850,000 ordinary shares at $0.01 per ordinary share Read the full story
Posted on 13 November 2014
Tags: AbbVie, diagnostic, partnering, personalized medicine
ENTEROME Bioscience has entered into a collaborative development agreement with AbbVie Read the full story
Posted on 04 November 2014
Tags: acquisition, diagnostic, M&A
Laboratory Corporation of America acquired Covance for $6.1 billion. Read the full story
Posted on 13 October 2014
Tags: diagnostic, diagnostics
The Molecular Diagnostics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. Read the full story
Posted on 13 October 2014
Tags: diagnostic, diagnostics, imaging
The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies. Read the full story
Posted on 24 July 2014
Tags: biomarker, diagnostic
QIAGEN sees potential for developing companion diagnostics to guide treatment with new anti-cancer compounds under development that target QIAGEN announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo. Read the full story
Posted on 15 April 2014
Tags: biotech, companion diagnostic, diagnostic, pharma deals
AVEO Oncology and Biodesix entered into a worldwide pharma alliance to develop and commercialize AVEO’s hepatocyte growth factor inhibitory antibody ficlatuzumab, with a Biodesix companion diagnostic test. Read the full story
Posted on 22 January 2014
Tags: diagnostic, genome, test
Personal Genome Diagnostics has licensed exclusive rights to a technology known as PARE from Johns Hopkins University that is enabling the company to successfully analyze cell-free tumor DNA circulating in patients’ blood. Read the full story
Posted on 25 November 2013
Tags: big pharma, diagnostic
Definiens and Metamark Genetics announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark. Read the full story